Aviamarin tablets 50mg, No. 10

• Motion sickness (sea, car and air sickness);

• prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by anticancer therapy;

• Meniere's disease.

Inside, before meals.

Motion sickness (sea, car and air sickness)

Children aged 3 to 6 years: 1 / 4-1 / 2 tablets 2-3 times / day.

Children aged 7-12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab. 2-3 times / day

Prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by anticancer therapy

Children aged 3 to 6 years: 1 / 4-1 / 2 tablets 2-3 times / day.

Children aged 7-12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab. 2-3 times / day

Meniere's disease

Children aged 3 to 12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab. 2-3 times / day The maximum daily dose for adults should not exceed 7 tablets.

For the prevention of kinetosis, 1-2 tablets should be taken 30 minutes before the trip. Duration of use of the drug and the possibility of repeating the course of treatment - in agreement with the doctor.

Tablets are white or almost white, round, flat-cylindrical, with a chamfer and a cross-shaped line.

1 tab.

Dimenhydrinate 50 mg

Excipients: microcrystalline cellulose, povidone (kollidone 30), crospovidone, mannitol, colloidal silicon dioxide (aerosil), magnesium stearate.

• Hypersensitivity to drug components;

• epilepsy;

• acute exudative and vesicular dermatoses;

• children under 3 years old;

• I trimester of pregnancy;

• period of breastfeeding.

  Carefully

• Convulsive syndrome, angle-closure glaucoma, prostatic hyperplasia, bronchial asthma, cardiovascular disease, hyperthyroidism, stenosing peptic ulcer, pyloroduodenal obstruction and bladder neck obstruction.

pharmachologic effect

Blocks histamine H1 receptors and m-cholinergic receptors of the central nervous system. Inhibits the vestibular apparatus of the inner ear, acting primarily on otoliths, in high doses - on the semicircular canals. It has antiemetic, anorexigenic, sedative effect, eliminates dizziness.

Pharmacokinetics

Absorption and distribution

After oral administration, dimensionhydrinate is well absorbed, distributed to organs and tissues. The effect of the drug manifests itself in 15-30 minutes and lasts for 3-6 hours. About 78% of dimensionhydrinate binds to blood plasma proteins.

Metabolism and excretion

Dimenhydrinate is metabolized in the liver and is almost completely excreted in the urine within 24 hours. Small amounts are excreted in breast milk. T1 / 2 of dimensionhydrinate is about 3.5 hours.

Side effect

From the side of the blood and lymphatic system: very rarely - hemolytic anemia, agranulocytosis, neutropenia, leukopenia, thrombocytopenia or pancytopenia. From the immune system: rarely - anaphylactic shock. Mental disorders: often - mood changes, anxiety, stiffness of movements; infrequently - insomnia. From the nervous system: often - drowsiness; infrequently - impaired balance, decreased concentration and memory impairment (more often in elderly patients), tremors, lack of coordination, confusion, hallucinations; rarely - headache, sleep disturbance, dizziness, orthostatic hypotension; very rarely - paradoxical stimulation of the central nervous system (especially in children). From the side of the organ of vision: rarely - glaucoma, vision problems (dilated pupil, blurred vision or double image).On the part of the organ of hearing and labyrinthine disorders: rarely - ringing in the ears. From the side of the heart: rarely - palpitations, tachycardia and hypotension. From the respiratory system, chest and mediastinal organs: often - nasal congestion. From the gastrointestinal tract: often - dry mouth, constipation, diarrhea, nausea, abdominal pain. From the liver and biliary tract: unspecified frequency - abnormal liver function (cholestatic jaundice). Skin and subcutaneous tissue disorders: rarely - rash, redness. On the part of the kidneys and urinary tract: often - violation of urination (urinary retention due to anticholinergic action). General disorders and disorders at the injection site: rarely - edema (less often - Quincke's edema). If any of the side effects indicated in the instructions are aggravated, or the patient has noticed any other side effects not listed in the instructions,he must inform his attending physician about this.

Application during pregnancy and lactation

The use of the drug in the II-III trimesters of pregnancy is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. The use of the drug in the first trimester of pregnancy and during breastfeeding is contraindicated. During treatment, breastfeeding should be discontinued.

Application in children

Contraindication: children under 3 years of age.

special instructions

Influence on the ability to drive vehicles and mechanisms

Given the side effects of dimensionhydrinate, caution should be exercised when engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions (including driving).

Overdose

Overdose symptoms: dry mouth, nose and throat, facial redness, slow and labored breathing, confusion, in children - convulsions, hallucinations. If these symptoms appear, an urgent need to consult a doctor. Treatment: gastric lavage with a suspension of activated carbon (20-30 g), the appointment of a saline laxative (10-15 g of sodium sulfate), symptomatic therapy, for convulsions in children - phenobarbital (5-6 mg / kg), diazepam.

Drug interactions

Dimenhydrinate enhances the effects of atropine, tricyclic antidepressants, catecholamines, barbiturates, ethanol, sedatives and hypnotics, antipsychotics. Dimenhydrinate weakens the effect of corticosteroids, anticoagulants. Dimenhydrinate reduces the response to apomorphine. Dimenhydrinate reduces the depressive effect of acetylcholine on the heart muscle. The combination with bismuth preparations, scopolamine, pain relievers and psychotropic drugs increases the likelihood of visual impairment. Incompatible with ototoxic antibiotics (streptomycin, neomycin, biomycin, amikacin, kanamycin), because Dimenhydrinate can mask the symptoms of ototoxicity and contribute to the development of irreversible hearing impairment.